Author: PharmaSignal News Desk

GSK asthma drug approval marks a significant milestone with FDA clearance of Exdensur for twice-yearly dosing, impacting severe asthma care.

Peanut allergy patch shows positive results in Phase 3 study, paving way for 2026 FDA submission.

RA Capital co-leads a $125 million Series A for Ambros Therapeutics, advancing a chronic pain drug nearing pivotal testing.

Addition Therapeutics secures $100M to advance RNA-lipid nanoparticle gene therapies, backed by Gates Foundation.

Nektar autoimmune drug shows promise in alopecia study, despite missing statistical success, supporting late-stage testing.

FDA fast pass J&J for multiple myeloma regimen, impacting treatment timelines.

Xoma acquires Generation Bio, a gene therapy developer, in a strategic move to enhance its biotech portfolio.

Argenx halts two Vyvgart trials for thyroid eye disease after interim results show ineffectiveness, impacting potential market expansion.

Sanofi Tolebrutinib setback includes a Phase 3 failure in primary progressive MS and a delayed US approval decision.

Arcus Gilead trial cancellation marks a setback in cancer research as the TIGIT/PD-1 study is halted for futility, impacting future strategies.